Your browser doesn't support javascript.
loading
Incorporation of lysozyme into a mucoadhesive electrospun patch for rapid protein delivery to the oral mucosa.
Edmans, Jake G; Murdoch, Craig; Santocildes-Romero, Martin E; Hatton, Paul V; Colley, Helen E; Spain, Sebastian G.
Afiliação
  • Edmans JG; School of Clinical Dentistry, 19 Claremont Crescent, University of Sheffield, Sheffield S10 2TA, UK; Department of Chemistry, Brook Hill, University of Sheffield, Sheffield S3 7HF, UK.
  • Murdoch C; School of Clinical Dentistry, 19 Claremont Crescent, University of Sheffield, Sheffield S10 2TA, UK.
  • Santocildes-Romero ME; AFYX Therapeutics, Lergravsej 57, 2. tv, 2300 Copenhagen, Denmark.
  • Hatton PV; School of Clinical Dentistry, 19 Claremont Crescent, University of Sheffield, Sheffield S10 2TA, UK.
  • Colley HE; School of Clinical Dentistry, 19 Claremont Crescent, University of Sheffield, Sheffield S10 2TA, UK. Electronic address: h.colley@sheffield.ac.uk.
  • Spain SG; Department of Chemistry, Brook Hill, University of Sheffield, Sheffield S3 7HF, UK.
Mater Sci Eng C Mater Biol Appl ; 112: 110917, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32409068
The delivery of biopharmaceuticals to the oral mucosa offers a range of potential applications including antimicrobial peptides to treat resistant infections, growth factors for tissue regeneration, or as an alternative to injections for systemic delivery. Existing formulations targeting this site are typically non-specific and provide little control over dose. To address this, an electrospun dual-layer mucoadhesive patch was investigated for protein delivery to the oral mucosa. Lysozyme was used as a model antimicrobial protein and incorporated into poly(vinylpyrrolidone)/Eudragit RS100 polymer nanofibers using electrospinning from an ethanol/water mixture. The resulting fibrous membranes released the protein at a clinically desirable rate, reaching 90 ± 13% cumulative release after 2 h. Dual fluorescent fibre labelling and confocal microscopy demonstrated the homogeneity of lysozyme and polymer distribution. High encapsulation efficiency and preservation of enzyme activity were achieved (93.4 ± 7.0% and 96.1 ± 3.3% respectively). The released lysozyme inhibited the growth of the oral bacterium Streptococcus ratti, providing further evidence of retention of biological activity and illustrating a potential application for treating and preventing oral infections. An additional protective poly(caprolactone) backing layer was introduced to promote unidirectional delivery, without loss of enzyme activity, and the resulting dual-layer patches displayed long residence times using an in vitro test, showing that the adhesive properties were maintained. This study demonstrates that the drug delivery system has great potential for the delivery of therapeutic proteins to the oral mucosa.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Portadores de Fármacos / Muramidase / Nanofibras Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Portadores de Fármacos / Muramidase / Nanofibras Idioma: En Ano de publicação: 2020 Tipo de documento: Article